Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2022 Apr;163(4):1393-1403.e9.
doi: 10.1016/j.jtcvs.2020.03.182. Epub 2020 Jun 25.

Nitric oxide delivery during cardiopulmonary bypass reduces acute kidney injury: A randomized trial

Nikolay O Kamenshchikov  1 , Yana J Anfinogenova  2 , Boris N Kozlov  3 , Yulia S Svirko  3 , Stanislav E Pekarskiy  2 , Vladimir V Evtushenko  2 , Vladimir A Lugovsky  2 , Vladimir M Shipulin  3 , Vladimir V Lomivorotov  4 , Yuriy K Podoksenov  3
Affiliations
Free article
Randomized Controlled Trial

Nitric oxide delivery during cardiopulmonary bypass reduces acute kidney injury: A randomized trial

Nikolay O Kamenshchikov et al. J Thorac Cardiovasc Surg. 2022 Apr.
Free article

Abstract

Objective: Acute kidney injury (AKI) is a serious complication of cardiac surgery with cardiopulmonary bypass (CPB). The aim of this study was to evaluate the effects of nitric oxide (NO) supplementation to the CPB circuit on the development of cardiac surgery-associated AKI.

Methods: This prospective randomized controlled study included 96 patients with moderate risk of renal complications who underwent elective cardiac surgery with CPB. The study protocol was registered at ClinicalTrials.gov (identifier NCT03527381). Patients were randomly allocated to either NO supplementation to the CPB bypass circuit (NO treatment group; n = 48) or usual care (control group; n = 48). In the NO treatment group, 40-ppm NO was administered during the entire CPB period. The primary outcome was the incidence of AKI.

Results: NO treatment was associated with a significant decrease in AKI incidence (10 cases [20.8%] vs 20 cases [41.6%] in the control group; relative risk, 0.5; 95% confidence interval, 0.26-0.95; P = .023) and a higher median urine output during CPB (2.6 mL/kg/h [interquartile range (IQR), 2.1-5.08 mL/kg/h] vs 1.7 mL/kg/h [IQR, 0.80-2.50 mL/kg/h]; P = .0002). The median urinary neutrophil gelatinase-associated lipocalin level at 4 hours after surgery was significantly lower in the NO treatment group (1.12 ng/mL [IQR, 0.75-5.8 ng/mL] vs 4.62 ng/mL [IQR, 2.02-34.55 ng/mL]; P = .005). In the NO treatment group, concentrations of NO metabolites were significantly increased at 5 minutes postclamping, at 5 minutes after declamping, and at the end of the operation. Concentrations of proinflammatory and anti-inflammatory mediators and free plasma hemoglobin did not differ significantly between the 2 groups.

Conclusions: NO administration in patients at moderate risk of renal complications undergoing elective cardiac surgery with CPB was associated with a lower incidence of AKI.

Keywords: acute kidney injury; cardiac surgery; cardiopulmonary bypass; nitric oxide.

PubMed Disclaimer

Comment in

Publication types

Associated data